Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride Injection for Prevention of Postoperative Nausea and Vomiting
CTR20222711Phase 3Completed
- Sponsor
- Beijing Pudekangli Pharmaceutical Technology Development
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Amisulpride injection with Placebo (2 arms). Primary endpoint: Complete response rate of PONV within 24 hours after surgery. Started Oct 2022; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on CTR20222711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222711.